THORN RUN PARTNERS for NOVARTIS CORPORATION
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 17, 2016 | $50,000 | Replaced |
| 4th Quarter - Amendment (this page) | Apr 19, 2016 | $70,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEX DELPIZZO | — |
| WILLIAM CHRISTOPHER LAMOND | — |
| ANDREW ROSENBERG | — |
| RICHARD CHARLES WHITE | — |
Taxation/Internal Revenue Code TAX
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEX DELPIZZO | — |
| WILLIAM CHRISTOPHER LAMOND | — |
| ANDREW ROSENBERG | — |
| RICHARD CHARLES WHITE | — |
Medicare/Medicaid MMM
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEX DELPIZZO | — |
| WILLIAM CHRISTOPHER LAMOND | — |
| ANDREW ROSENBERG | — |
| RICHARD CHARLES WHITE | — |
Medical/Disease Research/Clinical Labs MED
Issues related to biologics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEX DELPIZZO | — |
| WILLIAM CHRISTOPHER LAMOND | — |
| ANDREW ROSENBERG | — |
| RICHARD CHARLES WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.